Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.25.3
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue $ 0 $ 0 $ 0 $ 0
Operating expenses:        
Research and development 2,205 4,702 7,867 15,560
General and administrative 2,708 2,263 9,428 8,510
Total operating expenses 4,913 6,965 17,295 24,070
Other income/(expense):        
Interest (expense) income (212) 12 (406) 226
Foreign exchange loss 2 0 (8) (1)
Total other (expense) income (210) 12 (414) 225
Net loss and comprehensive loss $ (5,123) $ (6,953) $ (17,709) $ (23,845)
Basic loss per common share $ (2.01) $ (11.33) $ (7.34) $ (44.41)
Diluted loss per common share $ (2.01) $ (11.33) $ (7.34) $ (44.41)
Weighted average number of common shares outstanding used in the calculation of basic loss per share (in shares) 2,552,429 613,604 2,411,943 536,891
Weighted average number of common shares outstanding used in the calculation of diluted loss per share (in shares) 2,552,429 613,604 2,411,943 536,891